AsepticSure, a revolutionary decontamination technology designed to neutralize weaponized pathogens, hospital superbugs and all known food-borne bacteria, continues to expand its global patent protection program.
San Francisco, CA February 8, 2012. Medizone International, Inc. (MZEI:OB) MZEI:QB), the company behind the AJIC peer-reviewed disinfection technology AsepticSure, announced today that it has now completed National patent application filings of its recently granted lead patent application (Canadian Patent No 2735739). These filings apply to the United States, Mexico, Brazil, China, Japan, Korea, Singapore, the 37 countries of the European Patent Organization (EU), Great Britain, India and Australia.
AsepticSure’s clinically proven efficacy against a vast spectrum of pathogenic bacteria, fungi, spores and viruses clears the way for its use in large-scale reductions of hospital acquired infections (HAIs) in surgical centers, long-term care facilities and hospitals around the world.
It’s also the only green disinfection technology on the planet that has consistently demonstrated in peer-reviewed research, an unprecedented 100% kill-rate (> 6-log) with formidable pathogens such as C-difficile, MRSA, E coli, Pseudomonas aeruginous and VRE, the root sources of superbug infections – on both hard and soft surfaces – and without the need to remove, cover or protect the treated room’s contents.
Medizone’s lead patent was granted on November 22, 2011 by the Canadian Intellectual Property Office (patent office) for processes and systems relating to the platform technology. The Company considers this an extraordinarily strong foundational patent as it covers both the science and technology of AsepticSure.
Medizone Board Chairman and CEO, Edwin Marshall added, “Shareholders should also be delighted to know that our patent attorneys have recently received a most favorable report from the Patent Cooperation Treaty (PCT) Examiners on both the Bed Bug Application and our Bio-Terrorism Countermeasures Application for dealing with weaponized pathogens for building remediation following an attack.
“To quote, ‘The way forward to an international, favorable patentability opinion on each case seems to be clear. In no case has the examiner found any prior art of which we were not previously aware. In respect of the Anthrax case and the Bed Bugs case, there are no pertinent prior art references at all. All claims in both cases are ruled to possess both novelty and inventive step, so that they can proceed without further amendment or argument.’”
Marshall concluded, “As Medizone’s AsepticSure technology moves closer to becoming the International Standard for Disinfection of enclosed spaces, the significance of these patents to shareholder value moving forward should prove immense. It’s a great time to be involved with this Company.”
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com